Posters - Advanced Therapeutics in Movement & Related Disorders™

2024 Poster Information

2024 Poster Winners

Pilot Study of the Felix NeuroAI Wristband in Patients with Essential Tremor | P07

Richard Dewey III, MD; Stuart Isaacson, MD; Richard Dewey Jr. MD; Kelly Lyons, PhD; Anh Tuan Nguyen, PhD; Qi Zhao, PhD; Zhen Zhang, PhD; Rajesh Pahwa, MD

Improving Quality and Safety of Care for Hospitalized Patient’s with Parkinson’s Disease | P14

Patricia A. Clark, Anne Brooks, Hubert H. Fernandez, Olivia Hogue, Kim Lewin, Camila Piccinin, Shannon Shaffer, Brent S. Sokola, Claire Sonneborn, Scott A. Sperling, Benjamin L. Walter, Jeryl Ritzi T. Yu

Neurology Live interviewed poster submitter Patricia Clark about her findings. Watch here.

Duration of botulinum toxin efficacy in cervical dystonia clinical trials: a scoping review | P17-B

Anna Castagna, Hyder A. Jinnah, Alberto Albanese

All 2024 Posters Presented

The Huntington Disease Health Index (HD-HI): Measuring Changes in Disease Burden in Response to Valbenazine During the KINECT®-HD Trial | P01-A

Erin Furr Stimming, Daniel O. Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Sean C. Hinton, Olga Klepitskaya, Hui Zhang, Eduardo Dunayevich, Grace Liang, Dietrich Haubenberger

Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease | P01-B

Erin Furr Stimming, Daniel O. Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Sean C. Hinton, Olga Klepitskaya, Hui Zhang, Eduardo Dunayevich, Grace Liang, Dietrich Haubenberger

Cinema Therapy: rewriting the narrative of Parkinson’s | P02

Robert Cochrane, PhD

Increasing diverse enrollment in clinical research studies and available PD therapies by utilizing a variation of the train the trainer model to create best practice guidelines and to build a culturally sensitive and community educated team of ambassadors. | P03

Bernard and Denise Coley

Reductions in OFF time with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study | P04-A

Aaron L. Ellenbogen, Alberto J. Espay, Stuart Isaacson, Nelson Lopes, Nissim Sasson, Tami Yardeni, Werner Poewe

Onset of efficacy with continuous, subcutaneous levodopa/carbidopa infusion in patients with PD experiencing motor fluctuations | P04-B

Aaron L. Ellenbogen, Fabrizio Stocchi, Nelson Lopes

Lips Sealed: What Your Patients Aren’t Telling You | P05

Anissa Mitchell, LCSW

Patient Motivations for Advanced Treatment of Essential Tremor and Tremor-Dominant Parkinson’s Disease | P06

Regina Martuscello, Adam Lara, Nikki Swartswelder, Ramya Singh, Katie Gant, Augusto Grinspan

Pilot Study of the Felix NeuroAI Wristband in Patients with Essential Tremor | P07

Richard Dewey III, MD; Stuart Isaacson, MD; Richard Dewey Jr. MD; Kelly Lyons, PhD; Anh Tuan Nguyen, PhD; Qi Zhao, PhD; Zhen Zhang, PhD; Rajesh Pahwa, MD

Beyond Memory: A Bilingual Brain Health Awareness Workshop for Spanish-speaking Communities | P08

Alosilla M, Alvarez-Pizzillo C, Avion-Martinez S, Cabassa J, Cavedoni-Urbano B, Crawford L, De Leon M, Fernandez Toledo E, Moya-Gale G, Perez S, Walker-Pizarro N, Shah H

Treatment optimization of continuous subcutaneous apomorphine infusion (CSAI) added to PD medications and OFF time reduction during hours of CSAI use | P09-A

Alberto J. Espay MD, Peter A. LeWitt MD, Rajesh Pahwa MD, Andrea Formella PharmD, Peibing Qin, Stuart H. Isaacson MD

Continuous Subcutaneous Apomorphine Infusion (CSAI) Responder Rates During Titration: Observations from the Openlabel Phase 3 InfusON Trial | P09-B

Isaacson SH, Ceresoli-Borroni G, Espay AJ, Pahwa R, Agarwal P, Shill HA, Hui J, Dashtipour K, Lew M, Qin P, Formella A, Grall M, LeWitt PA

Proteomic Subtyping of Alzheimer’s Disease Reveals Distinct Molecular Signatures and Diverse Demographic Profiles | P10

Fatemeh Seifar, E. Kathleen Carter, Edward J. Fox, Lenora A. Higginbotham, Anantharaman Shantaraman, Lingyan Ping, Duc M. Duong, Philip L. De Jager, David A. Bennett, James J. Lah, Allan I. Levey, Nicholas T. Seyfried

Initiation of apomorphine hydrochloride injection (Apokyn) in the absence of an antiemetic in people with Parkinson’s disease | P11-A

Cindy Happel, Mindy Grall, Andrea Formella

Comparison of three oral amantadine formulations: a population pharmacokinetic study | P11-B

Zhao Wang, Roberto Gomeni, Robert A. Hauser, Rajesh Pahwa, Olivier Rascol, Asfiha Gebre, Andrea Formella, Gianpiera Ceresoli-Borroni, Jonathan Rubin

How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial | P12-A

Robert A. Hauser, MD, MBA, Ghazal Banisadr, PhD, Stanley Fisher, MD, Hester Visser, MD, PhD, Richard D’Souza, PhD

Extended-release carbidopa-levodopa: How is IPX203 different from IPX066? | P12-B

Robert A. Hauser, Aaron Ellenbogen, Ghazal Banisadr, Stanley Fisher, Richard D’Souza

Opicapone as First Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease | P13-A

Jee-Young Lee, Joaquim J. Ferreira, Hyeo-il Ma, José-Francisco Rocha, Beomseok Jeon, on behalf of Korean OGT_001 study investigators

OPICAPONE EFFECT ON SLEEP DISORDERS IN FLUCTUATING PARKINSON’S DISEASE PATIENTS: FINDINGS FROM THE OASIS EXPLORATORY TRIAL | P13-B

Joaquim Ferreira, Miguel Gago, Raquel Costa, Miguel Fonseca, Joana Almeida, José Rocha, Joerg Holenz, Claudia Trenkwalder

Improving Quality and Safety of Care for Hospitalized Patient’s with Parkinson’s Disease | P14

Patient characteristics and real-world use of botulinum toxins for treatment of hemifacial spasm | P15-A

Mike Hast, Amanda Kong, Shaina Desai, Soo Back, Jordan Holmes

Delphi analysis: optimising anatomy teaching and ultrasound training for botulinum neurotoxin type A injection in spasticity and dystonia | P15-B

Kimberly Heckert, Bo Biering-Sørensen, Tobias Bäumer, Omar Khan, Fernando Pagan, Mitchell Paulin, Todd Stitik, Monica Verduzco-Gutierrez, Rajiv Reebye

Patient characteristics and real-world use of botulinum toxins for treatment of chronic sialorrhea | P16-A

Mike Hast, Amanda Kong, Jenna Abdelhadi, Andrew Szendrey, Rohan Shah, Jordan Holmes

Patient characteristics and real-world use of botulinum toxins for treatment of cervical dystonia and blepharospasm | P16-B

Michael Hast, Amanda Kong, Shaina Desai, Sahar Syed, Jordan Holmes

Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease | P17-A

Bruno Bergmans, Veronica Clark, Stuart H. Isaacson, Tobias Bäumer

Duration of botulinum toxin efficacy in cervical dystonia clinical trials: a scoping review | P17-B

Anna Castagna, Hyder A. Jinnah, Alberto Albanese

Use of the Modified Functional Status Questionnaire to Assess Functioning in Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin | P18

Virgilio G. H. Evidente, MD; Lambros Chrones, MD; Ratna Revankar, PhD; Dilesh Doshi, PharmD, MS; Victor Abler, DO; Nazia Rashid, PharmD, MS

Interim analysis of Istradefylline effects on tremor in Parkinson’s disease patients – promising benefits on tremor control | P19

Gonul Ozay, Irma T Zhang, Michelle Umali, Luke Lovelace, Michael P Barry, Lina M Ariza Serrano, Alexandre Mason-Sharma, Lana Raslan, Yasar Torres-Yaghi, Fernando L Pagan

IMPROVEMENT OF MOTOR AND NON-MOTOR SYMPTOMS WITH BEZISTERIM (NE3107) ADJUNCTIVE TO CARBIDOPA/LEVODOPA IN PATIENTS WITH PARKINSON’S DISEASE: A PHASE 2A, PLACEBO-CONTROLLED STUDY | P20-A

Joseph Palumbo; Christopher L. Reading; Clarence Ahlem; Jeffrey Zhang; Jason L. Aldred; Ramon L. Rodriguez; Edgardo J. Rivera-Rivera; Stuart H. Isaacson; Rajeev Kumar; Aaron L. Ellenbogen; Anthony E. Lang

ASSESSMENT OF BEZISTERIM (NE3107) IN PATIENTS WITH EARLY PARKINSON’S DISEASE: A PHASE 2, PLACEBO-CONTROLLED STUDY | P20-B

Joseph Palumbo; Clarence Ahlem; Christopher L. Reading; Jeffrey Zhang; Mark Stacy

Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study | P21-A

Alberto Espay, Alberto Albanese, Aaron L. Ellenbogen, Joaquim J. Ferreira, Nir Giladi, Tanya Gurevich, Sharon Hassin-Baer, Jorge Hernandez-Vara, Stuart Isaacson, Karl Kieburtz, Peter LeWitt, Lydia Lopez-Manzanares, C. Warren Olanow, Rajesh Pahwa, Werner Poewe, Harini Sarva, Fabrizio Stocchi, Tami Yardeni, Liat Adar, Laurence Salin, Nelson Lopes, Nissim Sasson, Ryan Case, Olivier Rascol

Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612 | P21-B

Alberto Espay, Tanya Gurevich, David Arkadir, Sophia Sopromadze, Liat Adar, Ryan Case, Tami Yardeni

Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study | P22

Werner Poewe, Aaron L. Ellenbogen, Fabrizio Stocchi, Liat Adar, Laurence Salin, Ryan Case, Tami Yardeni, Nir Giladi

Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data | P23-A

Reversa Joseph MD., Joyce Qian PhD., Hannah Cummings PhD., Yen-Hua Chen MS., Shubham Tewari MS., Michael Soileau MD

Comparative Safety of Istradefylline Among Parkinson’s Disease Adjunctive Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Studies | P23-B

Comparative Safety of Istradefylline Among Parkinson’s Disease Adjunctive Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Studies

A Wearable-Sensors Substudy of KINECT®-HD, a Phase 3 Trial of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease | P24

Jamie L. Adams, Erin Furr Stimming, Daniel O. Claassen, Elise Kayson, Jody Goldstein, Sean C. Hinton, Olga Klepitskaya, Hui Zhang, Grace Liang, Kelly Lin, Sean Mitchell, Dietrich Haubenberger

Somnolence-Related Events Over Time with Valbenazine Treatment for Chorea Associated with Huntington’s Disease | P25

Erin Furr Stimming, Daniel O. Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Sean C. Hinton, Olga Klepitskaya, Hui Zhang, Shree Karpuram, Dao Thai-Cuarto, Grace Liang, Dietrich Haubenberger

Adherence patterns of istradefylline treatment in patients with Parkinson’s disease: A group-based trajectory analysis | P26

Etsuro Nakanishi, Toshiki Fukasawa, Katsumi Shinoda, Hiroo Shimoda, Satoru Ito, Shinji Asada, Satomi Yoshida, Sachiko Tanaka-Mizuno, Kayoko Mizuno, Ryosuke Takahashi, Koji Kawakami

Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation | P27-A

Per Odin, Thomas E Kimber, Bruno Bergmans, Eric Freire-Alvarez, Florin Gandor, Stuart H Isaacson, Sara Dhanani, Robert A Hauser, Marie O’Meara, Anna Jeong, Jia Jia, Resmi Gupta, Lars Bergmann, Megha Shah, Linda Harmer, Saritha Talapala, Jason Aldred

Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People With Parkinson’s | P27-B

Robert Hauser, Bruno Bergmans, Irene Malaty, Daniel Cobb, Jaclyn Homola, Lars Bergmann, Resmi Gupta, Jia Jia, Megha Shah, Kallol Chaudhuri

Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease | P28-A

Jason Aldred, Tove Henriksen, Manon Bouchard, Juan Carlos Martínez-Castrillo, Michael J. Soileau, Amy Spiegel, Lars Bergmann, Resmi Gupta, Pavnit Kukreja, David G. Standaert

Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study | P28-B

Michael Soileau, Rajeev Kumar, Zachary T. Baldwin, Connie H. Yan, Triza Brion, Alex Bellenger, JeeHee Suh, Megha B. Shah, Pavnit Kukreja, Maurizio F. Facheris, Anand Shewale, Jason Aldred